DexCom, Inc.
NASDAQ:DXCMMedical - Devices
+$0.90 today
- Market cap
- $30.78B
- Beta
- 1.44
- P/E (TTM)
- 29.9
- EPS (TTM)
- $2.42
Volume 4.25M
Average 5.43M
DXCM Net Income
Bottom-line profit, the starting point for calculating cash from operations.
DexCom, Inc.NASDAQ: DXCM
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows, but more slowly than its trailing trend
Q2 FY2026 net income of $249.1M rose 38.5% year over year, behind the +74.9% change in trailing-twelve-month net income. Sequentially, it rose 24.9% from the prior quarter. Over 3 fiscal years it compounded at +34.8% a year.
Context
- Net income amounted to 17.9% of revenue in FY2025, up 3.7 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 21 analysts of $1.03B (+22.7%) for the fiscal year ending Dec 2026, a slowdown from the +45.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $249.1M+24.9% QoQ
- Last fiscal yearDec 2025
- $836.3M+45.1% YoY
- LTMJun 2026
- $999.7M+74.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +38.5% | -8.8% | -47.4 pp |
| 1 year | +45.1% | +22.7% | -22.4 pp |
| 3-year CAGR | +34.8% | +17.8% | -17.0 pp |
| 5-year CAGR | +19.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 836.3M USD
- Year-over-year change
- +45.1%
- 4-year CAGR
- +52.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 836.3M | +45.1% |
| FY2024 | 2024-12-31 | 576.2M | +6.4% |
| FY2023 | 2023-12-31 | 541.5M | +58.7% |
| FY2022 | 2022-12-31 | 341.2M | +120.6% |
| FY2021 | 2021-12-31 | 154.7M | — |
Net Income vs competitors
How DXCM compares with its peers on the latest reported figures
- DXCM's LTM Jun 2026 net income of $999.7M is the largest of the 7 companies compared; the peer median is $76.81M.
- Its year-over-year change of +74.9% is the highest of 6, against a peer median of -6.4%.
- Net income amounts to 20.1% of revenue for DXCM, versus a peer median of 36.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $999.7M | +74.9% | +34.8% | 20.1% | |
| LTM Jun 2026 | $375.3M | +59.0% | +277.3% | 12.3% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $301M | — | +51.0% | 9.3% |
| LTM Mar 2026 | $94.55M | -48.6% | +29.3% | 9.2% | |
| LTM Mar 2026 | $87.19M | +17.8% | — | 214.2% | |
| LTM Mar 2026 | $66.44M | -6.4% | +4.2% | 60.3% | |
| LTM Mar 2026 | $32.35M | -27.8% | -12.5% | 152.6% | |
MMEDVMiniMed Group, Inc. | — | — | — | — | — |
| Peer median (excluding DXCM) | $76.81M | -6.4% | +29.3% | 36.3% | |
Competitors are the stored peer set for DXCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 154.7M | 341.2M | 541.5M | 576.2M | 836.3M |
| Depreciation & Amortization | 102M | 155.9M | 186M | 217.7M | 251.8M |
| Deferred Income Tax | (4.9M) | (21.6M) | (55M) | (43.8M) | 182.2M |
| Stock-Based Compensation | 113.4M | 126.5M | 150.8M | 170.4M | 159.6M |
| Change in Working Capital | (132M) | 27.7M | 3.2M | 108.8M | 103.4M |
| Accounts Receivables | (75.5M) | (199.9M) | (260.1M) | (35M) | (201.9M) |
| Inventory | (112.2M) | 49.3M | (252.6M) | 12.4M | (63.7M) |
| Accounts Payables | 58M | 295.1M | 466.5M | 211.7M | 347M |
| Other Working Capital | (2.3M) | (116.8M) | 49.4M | (80.3M) | 22M |
| Other Non-Cash Items | 209.3M | 39.8M | (78M) | (39.8M) | (92.6M) |
| Operating Cash Flow | 442.5M | 669.5M | 748.5M | 989.5M | 1.44B |
| Capital Expenditures | (389.2M) | (364.8M) | (236.6M) | (358.8M) | (363.5M) |
| Acquisitions (Net) | (30.2M) | (3.9M) | 0 | 0 | 0 |
| Purchases of Investments | (2.47B) | (2.27B) | (3.2B) | (2.66B) | (1.27B) |
| Sales of Investments | 2.67B | 2.13B | 2.95B | 2.82B | 2.16B |
| Other Investing Activities | 10.1M | (14.3M) | (17.6M) | (15.5M) | 600K |
| Investing Cash Flow | (216.1M) | (521.5M) | (507.2M) | (207.5M) | 536M |
| Debt Repayment | 0 | 0 | 443.3M | 0 | (1.21B) |
| Common Stock Issued | 20.3M | 22.5M | 26.6M | 28.2M | 28.1M |
| Common Stock Repurchased | 0 | (557.7M) | (688.7M) | (750M) | (500M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.9M) | (17.3M) | (99.8M) | (13M) | (7M) |
| Financing Cash Flow | 10.4M | (552.5M) | (318.6M) | (734.8M) | (1.69B) |
| Effect of Forex Changes | (1.4M) | (5.8M) | 1.5M | (7.4M) | 21.5M |
| Net Change in Cash | 235.4M | (410.3M) | (75.8M) | 39.8M | 311.8M |
| Free Cash Flow | 53.3M | 304.7M | 511.9M | 630.7M | 1.08B |
DexCom, Inc.
NASDAQ:DXCM
Intrinsic Alpha fair value
Locked
Current Price
$82.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.